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Abstract
Background: Atopy and allergic phenotypes are biologically characterized by an imbalanced T
helper cell response skewed towards a type 2 (TH2) immune response associated with elevated
serum immunoglobulin E (IgE) levels. Polymorphisms in cytokine genes might modulate regulation
of the TH1/TH2 balance. We thus aimed at reproducing our previous findings from a European
study population on the association of various cytokine polymorphisms with self-reported hay fever
as well as increased total and specific IgE levels in two comparable study populations.
Methods: Two prospective Caucasian cohorts were used. In the Basel center of the European
Community Respiratory Health Survey (ECRHS, n = 418) ten distinct cytokine polymorphisms of
putative functional relevance were genotyped. In the Swiss cohort Study on Air Pollution And Lung
Disease In Adults (SAPALDIA, n = 6003) two cytokine polymorphisms were genotyped. The
associations of these polymorphisms with atopy were estimated by covariance and logistic
regression analysis.
Results: We confirmed IL4, IL10, IL6 and IL18 as candidate genes for atopic health outcomes. In
the large, well-characterized SAPALDIA cohort the IL6(-174G>C) and IL18(-137G>C)
polymorphisms were associated with circulating total IgE concentrations in subjects with hay fever.
The IL18(-137G>C) polymorphism was also associated with the prevalence of hay fever.
Conclusion: Comprehensive characterization of genetic variation in extended cytokine candidate
gene regions is now needed. Large study networks must follow to investigate the association of risk
patterns defined by genetic predisposing and environmental risk factors with specific atopic
phenotypes.
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Background
Atopic diseases like hay fever, asthma and eczema affect
an increasing proportion of people and account for con-
siderable morbidity and loss of quality of life. No simple
pattern of inheritance has been shown and susceptibility
to atopic disease appears to be determined by an interac-
tion between environmental and genetic factors [1,2].
Cytokines have been shown to play a crucial role in the
balance between TH1 and TH2 immune responses com-
monly thought to underlie atopic disease [3].
In recent years polymorphisms in various cytokine genes
have been identified and indication of functional rele-
vance exists for some of them. They have been associated
with atopic disorders such as hay fever, asthma, eczema or
elevated IgE levels, though inconsistently in many cases.
We have previously investigated a combination of
cytokine polymorphisms that we judged to have a high
likelihood of functional relevance, with regard to risk of
atopy and hay fever in a subsample of the European Pro-
spective Investigation into Cancer and Nutrition (EPIC)
[4]. A novel finding of our study was the association of a
protective heterozygous effect of the IL6(-174C>G) poly-
morphism with the risk for hay fever and with IgE levels
in hay fever cases.
We aimed to replicate our previously observed associa-
tions in two distinct study populations of European-Cau-
casian origin that were comparable to the EPIC study. The
first study population is an asthma case over-sampled
subpopulation of the European Community Respiratory
Health Study (ECRHS)[5]. The second study population is
a population-based cohort, the Swiss Study on Air Pollu-
tion and Lung Disease In Adults (SAPALDIA) [6,7]. The
present research aims were i) to reproduce associations
between ten potentially functionally relevant cytokine
polymorphisms and atopic outcomes in the Basel ECRHS
sample and ii) to investigate two of the least well estab-
lished SNPs, IL6(-174G>C) and IL18(-137G>C) with
increased statistical power in the SAPALDIA cohort.
Materials and methods
Study populations
One study population was the Swiss subsample of the
European Community Respiratory Health Study
(ECRHS). The European-wide cohort comprised at base
line >10000 adult participants from 14 countries. Details
of this pan-European cohort study have been reported
elsewhere [5]. All participants of the Swiss ECRHS study
center Basel who had given blood samples for IgE meas-
urement and genotyping were included in the present
study (n = 418). The second study population included in
this paper is the Swiss Study on Air Pollution And Lung
Disease In Adults (SAPALDIA) [6,7]. We included SAPAL-
DIA participants with complete interview data, blood
measurements of atopy at baseline, and available DNA
samples for genotyping (n = 6003).
IgE measurements
ECRHS-Basel sample: Total serum IgE levels and the con-
centrations of specific IgE to airborne allergens (cat, house
dust mite, mold (Cladosporium) and timothy grass) were
analyzed using the ELISA-based CAP system (Pharmacia
Diagnostics, Uppsala, Sweden) [8]. Blood as well as inter-
view data for this current study were collected at the
ECRHS follow-up examination for the investigation of
cross-sectional associations [9]. The measurement range
for total IgE was 2 to 2000 kU/L and for specific IgE 0.35
to 100 kU/L. No measurements of total as well as specific
IgE were obtainable from 21 ECRHS subjects of the Basel
center. SAPALDIA: Circulating serum levels of total IgE
and Phadiatop test were measured at baseline using the
CAP FEIA system (Pharmacia Diagnostics, Uppsala, Swe-
den). Interview data was also obtained at baseline for
cross-sectional analysis [6]. DNA for genotype analysis
was extracted from blood samples collected at follow-up
[7].
Cases and controls
ECRHS-Basel sample: Irrespective of self-reporting of
asthma or eczema, self-reported hay fever cases (n = 192)
were defined by answering yes to the question: 'Have you
ever had a problem with sneezing or a runny nose or a
blocked nose when you did not have a cold or a flue?'.
Irrespective of self-reporting of hay fever or eczema, phy-
sician-diagnosed asthma cases (n = 78) were defined by
answering yes to both questions: 'Have you ever had
asthma? Was this confirmed by a doctor?'. Irrespective of
self-reporting asthma or hay fever, eczema cases (n = 200)
were defined by answering yes to the question: 'Have you
ever had eczema or any other kind of skin allergy?'. Partic-
ipants who reported the absence of hay fever, eczema and
asthma were defined as non-atopic controls (n = 125).
Participants exhibiting total IgE levels higher than 100
kU/L were defined as "elevated total IgE cases". "Allergen
sensitization cases" were defined by exhibiting at least one
airborne allergen specific IgE higher than 0.35 kU/L.
SAPALDIA cohort: The assessment of total IgE level and
of various atopic disease outcomes in SAPALDIA was
identical to the ECRHS study. In accordance with the def-
initions provided for ECRHS above, 1168 participants
were defined as "elevated total IgE cases", 1105 partici-
pants as hay fever cases, 188 as asthma cases and 1837 as
eczema cases. 2953 participants were identified as non-
atopic controls. The "allergen sensitization cases" in the
SAPALDIA cohort were defined by a positive result in the
Phadiatop test (n = 1620).Clinical and Molecular Allergy 2006, 4:9 http://www.clinicalmolecularallergy.com/content/4/1/9
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Cytokine genotypes
Genomic DNA was extracted manually using the Pure-
geneTM DNA Isolation Kit (Gentra Systems, Plymouth,
MN, USA) for the ECRHS [9] and the SAPALDIA cohort
[7]. In the ECRHS sample, RFLP and allele specific PCR
was used for identification of the genetic polymorphisms
as previously described [4]. Ten single nucleotide poly-
morphisms (SNP) were investigated in nine cytokine
genes; SNP identification numbers (dbSNP:rs#) are listed
in Table 2. Genotyping was conducted at the German
Cancer Research Center under the supervision of one of us
(AN). Genotyping failed in 8 samples for polymorphisms
IL4R Q576R (A>G) and CD14(-159C>T), in 3 samples for
IL6(-174G>C) and IL13 R130Q (A>G), in 2 samples for
IL10(-819C>T) and TNF(-308G>A), in 1 sample for
IL10(-1082G>A), IL12p40(1188A>C) and IL18(-
137G>C). The considerably larger DNA sample collection
of the SAPALDIA cohort (n>6000) were processed in a
semi-automated medium throughput setup, assisted by
liquid handling station (THEONYX, MWG, München,
Germany) and subsequent 5'-nuclease fluorescent real-
time PCR (TaqMan) genotyping assay was applied
(Applera Europe, Rotkreuz, Switzerland). End-point
detection was done using a 7000 ABI System detection
device (ABI, Rotkreuz, Switzerland). Genotyping was con-
ducted at the Institute of Medical Genetics, Zürich, under
the supervision of one of us (MI). Genotyping failed in 16
samples for IL6(-174G>C) assay. Random re-genotyping
of >5% of the samples showed a high reproducibility
(>99.5%).
Statistical analysis
Hardy-Weinberg equilibrium was tested using Arlequin
Version 2.000 [10]. Genotype distribution for all cytokine
SNPs was found to be in Hardy Weinberg equilibrium in
both study populations. For the determination of an age-
and sex-adjusted association between genotype and
dichotomized phenotype (disease) we computed odds
ratios (ORs), p-values and the corresponding 95% confi-
dence limits (95%CI) using the STATA procedure LOGIS-
TIC with dummy variables for the respective genotypes
and with the most frequent allele as reference category. To
assess the age-and sex-adjusted association between geno-
type and continuous phenotypes we computed adjusted
means and p-values for group differences using the STATA
procedure ONEWAY. Total IgE levels were log-trans-
formed for analysis to achieve normal distribution.
Adjusted means presented are geometric means. Statistical
analysis was performed using STATA Version 8.1 SE (Stata
Corporation, TX, USA). Two-sided P-values of <0.05 were
considered as statistically significant. To correct for multi-
ple comparison, we applied the Bonferroni correction (60
comparisons in the ECRHS sample and 28 comparisons
in the SAPALDIA sample).
Results
The two study populations were comparable with regard
to the proportion of female participants and average age
(Table 1). The ECRHS participants had a narrower age
range and asthmatics had been over-sampled leading to
increased proportions of hay fever, eczema cases, and
atopy when compared to the SAPALDIA study cohort rep-
resentative of the adult Swiss general population. We ana-
lyzed a panel of ten SNPs in nine different cytokine genes
Table 1: Characteristics1) of the study populations and genotype distribution.
ECRHS-Basel N = 418 (%) SAPALDIA N = 6003 (%)
Female proportion 211 (50.5) 3022 (50.3)
Age [years] 43.4 (± 7.0) 41.3 (± 11.4)
Age range [years] 29.3 to 55.1 18.2 to 61.8
Hay fever cases2) 192 (45.9) 1105 (18.4)
Asthma cases3) 78 (18.2) 369 (6.2)
Eczema cases4) 200 (47.9) 2383 (39.7)
Elevated total IgE cases5) 101 (24.9) 1168 (21.6)
Allergen sensitization cases6) 178 (42.6) 1620 (29.1)
Non-atopic controls7) 125 (29.9) 2953 (49.2)
1) Presented in N (%) for categorical and in mean (± SD) for continuous variables.
2) Self-reported hay fever cases answered yes to, Have you ever had a problem with sneezing or a runny nose or a blocked nose when you did not 
have a cold?', irrespective of self-reported asthma or eczema.
3) Physician-diagnosed asthma cases answered twice yes to 'Have you ever had asthma? Was this confirmed by a doctor?', irrespective of self-
reported hay fever or eczema.
4) Self-reported eczema cases answered yes to 'Have you ever had eczema or any other kind of skin allergy?', irrespective of self-reported asthma or 
hay fever.
5) Elevated total IgE cases had serum total IgE level >100 kU/L, measured by CAP system (Pharmacia)
6) Allergen sensitization cases had at least one allergen specific IgE >0.35 kU/L, measured by CAP system (Pharmacia) for ECRHS-BS and by 
Phadiatop test (CAP FEIA system, Pharmacia) for SAPALDIA.
7) Non-atopic controls were free of self-reported hay fever, self-reported eczema and physician-diagnosed asthma.Clinical and Molecular Allergy 2006, 4:9 http://www.clinicalmolecularallergy.com/content/4/1/9
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in the ECRHS-Basel study population. Two of these SNPs,
IL18(-137G>C) and IL6(-174G>C), were also genotyped
in the SAPALDIA study cohort.
The characteristics of the study populations are provided
in Table 1. The age- and sex-adjusted association of each
of the cytokine SNPs with self-reported hay fever in the
Basel ECRHS study is presented in Table 2. None of the
polymorphisms was associated with the prevalence of hay
fever.
Age- and sex-adjusted associations of the cytokine SNPs
with atopy, assessed by elevated total circulating IgE are
presented in Table 3. Homo- or heterozygosity for the
IL10(-819) T-allele was more prevalent among subjects
with elevated total IgE levels than homozygosity for the C-
allele (OR for CT genotype: 1.81; 95%CI 1.12–2.92 and
OR for TT genotype: 1.96; 95%CI 0.82–4.67). The IL4(-
589C>T) TT genotype was more prevalent among elevated
total IgE cases (OR: 3.89; 95%CI 1.24–12.15). Homozy-
gosity of the IL18(-137) C-allele was more prevalent
among subjects with high total IgE levels compared to
subjects with low total IgE levels (OR: 2.51; 95%CI 1.21–
5.20) in the ECRHS-Basel sample.
We also analyzed the associations between cytokine SNPs
and total circulating IgE levels, stratified by the presence
of hay fever (data not shown). No statistically significant
associations between any SNP and IgE levels were
observed among subjects without atopic disease. Total IgE
levels were elevated among participants with hay fever
exhibiting IL4(-589C>T) TT genotype (p = 0.02). Hay
fever cases exhibiting IL4R Q576R GG, IL10(-819) TT or
IL18(-137) CC genotype had also increased total IgE lev-
els, although not significant due to low statistically power.
Given the inconsistencies of the results observed for the
two IL6 and IL18 SNPs when compared to our previous,
novel finding from the EPIC substudy [4], we further
investigated the role of these two SNPs in the larger SAPA-
LDIA cohort.
In Tables 4, 5 and 6 we present the relationship of IL6 and
IL18 SNPs with self-reported hay fever, and increased total
IgE and specific allergen sensitization. For the IL18(-
137G>C) SNP, we observed a statistically significant asso-
ciation with the risk of hay fever for heterozygous carriers
compared to homozygous GG genotypes (OR: 1.24, 95%
CI: 1.07 – 1.43, P = 0.004; Table 4). No other association
of IL18 SNP with atopy biomarkers was observed. How-
ever among hay fever cases IL18(-137) CC genotype was
associated with increased total IgE levels (P = 0.01; Table
6). For the IL6(-174G>C) SNP, no significant sex and age
adjusted association was observed for questionnaire-
based atopy reports, however for atopy biomarkers we
observed an inverse association for heterozygotes of the
IL6(-174G>C) with serum IgE levels >100 kU/L(OR: 0.83,
95% CI: 0.71–0.97, P = 0.02; Table 5). Subjects with IL6(-
174) GG genotype exhibited higher total serum IgE levels
than subjects with IL6(-174) GC or CC genotypes if they
reported hay fever (Table 6). No statistically significant
associations were observed of IL18 and IL6 genotypes
with asthma or eczema (data not shown).
Discussion
Our results from the ECRHRS Basel and the SAPALDIA
studies confirmed previously reported associations of
genetic variation in IL4, IL10, and IL18 cytokine genes
with atopic phenotypes. In addition, in the large SAPAL-
DIA cohort we were able to confirm the previously
reported, novel association between the IL6(-174G>C)
genotype and atopic phenotypes. Homozygosity for the
G-allele was associated with increased total serum IgE
concentrations in subjects reporting hay fever.
IL4 and IL10 has long been investigated as potential can-
didate genes for asthma and atopy [11]. IL4 is a pleio-
trophic TH2 cytokine and impacts on the development of
asthma and atopy in part through its role in the differen-
tiation to a TH2 phenotype of T cells. Moreover IL4 is
responsible for the class-switching from IgM to IgE.
Genetic variation in the IL4 gene has shown linkage to
atopy and asthma in several studies; common promoter
polymorphisms including the IL4(-589C>T) SNP have
been associated with asthma and/or atopy in many stud-
ies [12]. IL10 is an anti-inflammatory cytokine that sup-
presses the TH1-response and promotes B-cell activation
as well as regulates immunoglobulin class switching.
According to in vitro tests, IL10 regulates IgE production
and reduces IgE switching in the presence of IL4. Various
SNPs and haplotypes in the IL10 have been associated
with atopic phenotypes including circulating IgE concen-
trations [13].
The observed associations between the IL18 SNP and hay
fever or atopy are consistent with IL18 being a determi-
nant of TH1 and TH2 differentiation. IL18 has been sug-
gested to play a pleiotrophic role in the TH1/TH2 balance
[14,15]. Recent evidence suggests that IL18 and genetic
variation in this gene are associated with atopy [16-19]
and asthma [19-22]. The SNP investigated has been
shown to be functionally relevant in vitro; the position (-
137) of the IL18 promoter is part of the binding site for
nuclear transcription factors [23]. Depending on the pres-
ence of a G- or C-nucleotide at this polymorphic site, dif-
ferent transcription factors have been suggested to
recognize it and thus might differentially activate the
gene.Clinical and Molecular Allergy 2006, 4:9 http://www.clinicalmolecularallergy.com/content/4/1/9
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We were able to confirm our previously reported, novel
finding of an association between IL6 genotype and
atopic phenotypes by observing elevated IgE concentra-
tions among G/G genotypes. Contrary to our findings
from the EPIC cohort, we could not replicate the associa-
tion with the prevalence of hay fever in the large SAPAL-
DIA cohort, though [4]. Increasing evidence implicates
IL6 in promoting the development of TH2 mediated dis-
eases, like allergies (reviewed in [4]). In addition, this
cytokine and its genetic variants have more commonly
been associated with pro-inflammatory and specifically
with acute phase inflammation states. Indirect involve-
ment of IL6 in the etiology of environmentally induced
atopy and development of asthma can therefore not be
excluded. For example it is known that air pollution expo-
sure acts through oxidative stress promoting inflamma-
tory processes and thus might increase the risk of atopic
airway exacerbations and disease development [24]. Cir-
culating IL6 concentrations have been shown to be
increased in children exposed to air pollution [25].
This current study has several strong aspects. First, we pur-
sued a focused candidate gene approach. Our primary
goal was the replication of findings from our previous
Table 2: Adjusted1) associations of 10 cytokine polymorphisms with self-reported hay fever in the ECRHS-Basel Study.
Genotype cases/controls2) Odds Ratio 95% Confidence 
Interval
P-value
IL4 (-589C>T) CC 140/89 1 -- --
rs2243250 CT 47/31 0.99 0.58 – 1.68 0.98
TT 5/5 0.56 0.16 – 2.03 0.38
IL4R Q576R (A>G) AA 128/71 1 -- --
rs1801275 AG 58/45 0.68 0.42 – 1.13 0.12
GG 5/5 0.59 0.16 – 2.11 0.39
IL6(-174G>C) GG 65/33 1 -- --
rs1800795 GC 97/66 0.77 0.45 – 1.30 0.32
CC 28/25 0.58 0.29 – 1.15 0.12
IL10 (-1082G>A) GG 60/48 1 -- --
rs1800896 GA 96/50 1.58 0.94 – 2.6 0.08
AA 36/26 1.15 0.61 – 2.18 0.66
IL10 (-819C>T) CC 102/71 1 -- --
rs1800871 CT 77/42 1.26 0.77 – 2.04 0.35
TT 11/12 0.64 0.27 – 1.54 0.32
IL12p40(1188A>C) AA 114/74 1 -- --
rs3212227 AC 69/44 0.99 0.61 – 1.59 0.95
CC 9/6 1.05 0.36 – 3.09 0.93
IL13 R130Q (A>G) GG 127/82 1 -- --
rs20541 GA 57/38 0.96 0.58 – 1.58 0.87
AA 6/4 0.99 0.27 – 3.68 0.99
IL18(-137G>C) GG 101/55 1 -- --
rs187238 GC 73/54 0.75 0.46 – 1.22 0.25
CC 18/15 0.65 0.30 – 1.39 0.27
TNF(-308G>A) GG 135/84 1 -- --
rs1800629 GA 53/35 0.94 0.57 – 1.57 0.83
AA 4/4 0.58 0.14 – 2.40 0.45
CD14 (-159C>T) CC 49/41 1 -- --
rs2569190 CT 89/55 1.36 0.79 – 2.32 0.26
TT 51/26 1.64 0.88 – 3.09 0.12
1) Adjusted for age and gender.
2) Hay fever cases answered yes to 'Have you ever had a problem with sneezing or a runny nose or a blocked nose when you did not have a cold?', 
irrespective of self-reported asthma or eczema. Non-atopic controls were free of self-reported hay fever, self-reported eczema and physician-
diagnosed asthma.Clinical and Molecular Allergy 2006, 4:9 http://www.clinicalmolecularallergy.com/content/4/1/9
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study in two comparable populations. Our previous study
already focused on polymorphisms with a strong prior
hypothesis for potential association with atopy based on
both, previous reports from association studies as well as
functional studies of the SNPs [4]. Second, our results are
in line with well established associations of SNPs in IL4(-
589C>T) [11,12,26,27] and IL10 [11,27] with asthma
[11,12,28] and atopy [26,27,29]. We also observed a pos-
itive association of CD14(-159C>T) with asthma (data
not shown), an association that has also previously been
observed [28]. These results support the validity of the
results obtained from the ECRHS-Basel sample despite its
restricted sample size. Third, the extensive sample size and
detailed characterization of the SAPALDIA cohort study
provided a setting to corroborate with sufficient statistical
power the potential role of genetic variation in IL18 and
even more importantly in IL6 in the etiology and progres-
sion of atopic diseases.
A limitation of the ECRHS part of the study was the small
sample size. Accordingly, none of the statistically signifi-
cant results withheld the conservative correction for mul-
tiple testing. Applying the Bonferroni correction to the
ECRHS results lead to a revised significance level of
Table 3: Adjusted1) associations of 10 cytokine polymorphisms with elevated serum levels of total IgE in the ECRHS-Basel Study.
Elevated total IgE cases2)
Genotype cases/controls3) Odds Ratio 95% Conficence 
Interval
P-value
IL4 (-589C>T) CC 69/227 1 -- --
CT 25/81 1 0.57 – 1.65 0.91
TT 7/6 3.89 1.24 – 12.15 0.02
IL4R Q576R (A>G) AA 67/194 1 -- --
AG 30/105 0.91 0.55 – 1.50 0.71
GG 4/9 1.31 0.38 – 4.51 0.67
IL6(-174G>C) GG 34/98 1 -- --
GC 49/151 0.91 0.54 – 1.52 0.71
CC 18/62 0.80 0.41 – 1.56 0.52
IL10 (-1082G>A) GG 35/112 1 -- --
GA 54/137 1.22 0.74 – 2.01 0.44
AA 12/64 0.55 0.27 – 1.16 0.12
IL10 (-819C>T) CC 44/180 1 -- --
CT 48/112 1.81 1.12 – 2.92 0.02
TT 9/20 1.96 0.82 – 4.67 0.13
IL12p40(1188A>C) AA 61/183 1 -- --
AC 39/112 1.03 0.64 – 1.66 0.89
CC 1/18 0.16 0.02 – 1.20 0.08
IL13 R130Q (A>G) GG 68/206 1 -- --
GA 28/96 0.82 0.49 – 1.37 0.46
AA 5/9 2.14 0.67 – 6.78 0.19
IL18(-137G>C) GG 43/163 1 -- --
GC 42/127 1.22 0.75 – 2.00 0.42
CC 16/24 2.51 1.21 – 5.20 0.01
TNF(-308G>A) GG 66/220 1 -- --
GA 33/85 1.41 0.86 – 2.32 0.17
AA 2/7 1.18 0.23 – 5.98 0.84
CD14 (-159C>T) CC 24/88 1 -- --
CT 55/140 1.44 0.83 – 2.52 0.19
TT 21/79 0.97 0.50 – 1.90 0.94
1) Adjusted for age and gender.
2) Elevated total IgE cases had serum IgE level >100 kU/L, measured by CAP system (Pharmacia Diagnostics). Controls had IgE = 100 kU/L.
3) Controls had IgE = 100 kU/LClinical and Molecular Allergy 2006, 4:9 http://www.clinicalmolecularallergy.com/content/4/1/9
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0.0008 (60 comparisons) and according corrections to the
results obtained in SAPALDIA study lead to a revised sig-
nificance level of 0.0017 (28 comparisons). We chose to
present the uncorrected results because a) several of the
statistical tests performed were not independent, and b)
all association tested reflected an a priori hypothesis of the
study.
The rather low reproducibility of the observed associa-
tions for additional SNPs across the three studies is con-
sistent, though, with the generally poor reproducibility of
many genotype-disease associations [30]. Likely explana-
tions for the lack of replication include insufficient power,
population stratification and differences in linkage dise-
quilibrium between study population [30], chance find-
ings and publication bias, as well as heterogeneity in
genetic and environmental modifiers of specific gene/dis-
ease associations. We evaluated here only a small number
of selected genes and of specific SNP, yet other genes and
more importantly other sites of genetic variations should
be explored in future association studies. Of specific rele-
vance to the future investigation of genetic variation in
cytokine genes is the comprehensive identification of
genetic variation and common haplotypes in the accord-
ing gene regions [12, 31]. This seems of special relevance
since many of the cytokine genes are found in chromo-
somal clusters [31]. Genetic variants within and between
different cytokine genes are therefore likely to be in strong
linkage disequilibrium.
Conclusion
The results of this replication study further establish IL4,
IL10, IL18 and IL6 as candidate genes for atopic health
outcomes. Future networks of studies must now focus on
comprehensively characterizing genetic variation in
extended regions of these cytokine genes. The investiga-
tion of gene-gene-interactions seems essential given our
understanding of the complex interplay between various
cytokines in each others regulation. Finally, potential
modification of genotype and haplotype effects by envi-
Table 5: Adjusted1) association of IL6(-174G>C) and IL18(-137G>C) with elevated total IgE levels2) and allergen sensitization3)in the 
SAPALDIA Cohort Study.
Elevated total IgE Allergen sensitization (Phadiatop)
Genotype cases/
controls4)
Odds 
Ratio
95% 
Confidenc
e Interval
P-value cases/
controls4)
Odds 
Ratio
95% 
Confidenc
e Interval
P-value
IL6(-
174G>C)
GG 462/804 1 -- 596/1445 1 --
GC 515/1078 0.83 0.71 – 0.97 0.02 768/1873 1 0.88 – 1.13 0.97
CC 187/348 0.94 0.76 – 1.16 0.54 250/618 0.99 0.83 – 1.18 0.95
IL18(-
137G>C)
GG 631/1237 1 -- 860/2167 1 --
GC 447/831 1.07 0.92 – 1.24 0.40 635/1504 1.1 0.95 – 1.21 0.26
CC 90/164 1.07 0.82 – 1.41 0.61 125/275 1.1 0.91 – 1.43 0.27
1) Adjusted for age and gender. 2) Elevated total IgE cases had serum levels of total IgE >100 kU/L, measured by CAP system (Pharmacia 
Diagnostics). 3) Allergen sensitization cases had at least one positive allergen specific signal, measured by Phadiatop test using CAP FEIA system 
(Pharmacia Diagnostics). 4) Controls had total IgE ≤ 100 kU/L or were negative for all specific allergen tested (Phadiatop).
Table 4: Adjusted1) association of IL6(-174G>C) and IL18(-137G>C) with hay fever2) in the SAPALDIA Cohort Study.
Hay fever
Genotype cases/controls3) Odds Ratio 95% Confidence 
Interval
P-value
IL6(-174G>C) GG 393/1112 1 --
GC 537/1386 1.1 0.95 – 1.29 0.21
CC 169/451 1.04 0.84 – 1.28 0.74
IL18(-137G>C) GG 555/1619 1 --
GC 468/1117 1.24 1.07 – 1.43 0.004
CC 82/217 1.08 0.82 – 1.42 0.60
1) Adjusted for age and gender. 2) Self-reported hay fever cases answered yes to 'Have you ever had a problem with sneezing or a runny nose or a 
blocked nose when you did not have a cold?', irrespective of self-reported asthma or eczema. 3) Non-atopic controls were free of self-reported hay 
fever, self-reported eczema and physician-diagnosed asthma. 4) Controls had total IgE ≤ 100 kU/L or were negative for all specific allergen tested 
(Phadiatop).Clinical and Molecular Allergy 2006, 4:9 http://www.clinicalmolecularallergy.com/content/4/1/9
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ronmental and lifestyle factors and specific disease pheno-
types will further help to clarify our understanding of
atopic disease.
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